Drug Profile
LCI 1
Alternative Names: LCI-1Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics; Small molecules
- Mechanism of Action Checkpoint kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Cancer(Combination therapy) in USA
- 19 Nov 2009 Clinical trials in Cancer in USA (unspecified route)